Photodynamic therapy composition

Patent metadata

Field	Value
Publication number	US-12465651-B2
Application number	US-202217901299-A
Country	US
Kind code	B2
Filing date	Sep 1, 2022
Priority date	Feb 15, 2013
Publication date	Nov 11, 2025
Grant date	Nov 11, 2025

Abstract

A polymerizable phthalocyanine compound having the formula (I) or a PSMA-targeted phthalocyanine compound conjugate thereof having the formula (V).

First claim

Having described the invention, I claim:

1 . A PSMA-targeted phthalocyanine compound of formula VII:

or a pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition for treating cancer in a subject, the composition comprising a plurality of PSMA-targeted phthalocyanine compounds of formula (VII):

or a pharmaceutically acceptable salt thereof;
and wherein the PSMA targeting moiety targets the composition to a PSMA expressing cancer cell.

3 . The pharmaceutical composition of claim 2 , further comprising a pharmaceutically acceptable carrier.

4 . A method for treating a PSMA expressing cancer in a subject, the method comprising:
(a) administering to the subject with PSMA expressing cancer a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition including a plurality of PSMA-targeted phthalocyanine compounds of formula VII:

 or a pharmaceutically acceptable salt thereof;
and wherein the PSMA targeting moiety targets the PSMA-targeted phthalocyanine compounds to a PSMA expressing cancer cell;
(b) detecting PSMA-targeted phthalocyanine compounds bound to and/or complexed with the cancer cells to determine the location and/or distribution of the cancer cells in the subject; and
(c) irradiating the detected PSMA-targeted phthalocyanine compounds, thereby inducing the cytotoxic effects of the phthalocyanine compound on the cancer cells.

5 . The method of claim 4 , further comprising the steps of:
surgically resecting the cancer in the subject, wherein the detected PSMA-targeted phthalocyanine compounds bound to and/or complexed with the cancer cells guide surgical resection of the cancer; and irradiating the PSMA-targeted phthalocyanine compounds at the site of surgical resection, thereby inducing the cytotoxic effects of the PSMA-targeted phthalocyanine compounds on residual cancer cells following surgical resection.

6 . The method of claim 5 , wherein the surgical resection site is irradiated with an amount of radiation effective to inhibit tumor recurrence in the subject.

7 . The method of claim 5 , wherein intra-operative imaging (IOI) of the PSMA-targeted phthalocyanine compounds bound to and/or complexed with the cancer cells defines a tumor margin in the subject to guide surgical resection of the cancer.

8 . The method of claim 4 , wherein the PSMA expressing cancer is selected from the group consisting of renal carcinoma, transitional cell carcinoma of the urinary bladder, testicular embryonal carcinoma, colonic adenocarcinoma, neuroendocrine carcinoma, gliobastoma multiforme, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue carcinoma, breast carcinoma, and prostatic adenocarcinoma.

Assignees

• Univ Case Western Reserve

Inventors

• Basilion James

Classifications

• A61K49/0056

  Peptides, proteins, polyamino acids · CPC title

• A61K49/0036

  Porphyrins (used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546) · CPC title

• A61K41/0071

  PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines · CPC title

• A61K31/695 Primary

  Silicon compounds · CPC title

• A61K47/645

  Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT · CPC title